Work

Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.99

Authors: Amit D Raval, Guifang Chen, Matthew J. Korn, Andreas Bernthaler, Niculae Constantinovici, Stephen J. Freedland

Institutions: Bayer (United States), Bayer (Germany), Bayer (Switzerland), Cedars-Sinai Medical Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407699205

Cites:

Cited by: 1

Related to: 10